Immunomodulatory peptides from IgSF proteins: A review

Mythily Srinivasan, Roger W. Roeske

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The immunoglobulin (Ig) domain is a highly conserved domain predominantly observed in cell surface proteins due to its ability to resist proteolysis. By mutation and selection the Ig domain has evolved to serve diverse biological functions including growth and development, signaling, adhesion and protein-carbohydrate interactions. Collectively, proteins with Ig-like domain constitute the immunoglobulin superfamily (IgSF). The IgSF proteins make up over 2% of human genes constituting the largest gene family in the human genome. Analogous to the complementarity determining regions (CDR)s that form the antigen combining sites of the antibody, the high specificity of the IgSF receptor-ligand interaction is attributed to the sequence and structure of the CDR-like regions unique to each IgSF protein. Hence, CDR-like regions provide ideal templates for the design of mimetics that can potentially perturb specific IgSF receptor/ligand interactions. The determinants of binding are localized near the CDR-like regions, conformation is determined locally and is unique for each loop. In structure based drug design one of the approaches to identify lead agents is to map the receptor/ligand binding epitope onto a small peptide. Data from theoretical, structural and functional studies have been adopted in the design of novel peptide antagonists of the IgSF protein-protein interactions. Many peptide antagonists have shown significant therapeutic potential in multiple animal models. The design of the IgSF peptide analogs, rationale as therapeutic targets, functional efficacy and the clinical benefits are reviewed here.

Original languageEnglish
Pages (from-to)185-196
Number of pages12
JournalCurrent Protein and Peptide Science
Volume6
Issue number2
DOIs
StatePublished - Apr 2005

Fingerprint

Staphylococcal Protein A
Immunoglobulins
Complementarity Determining Regions
Peptides
Proteins
Ligands
Genes
Antibody Specificity
Drug Design
Human Genome
Growth and Development
Proteolysis
Epitopes
Membrane Proteins
Animal Models
Binding Sites
Carbohydrates
Antigens
Mutation
Conformations

Keywords

  • IgSF
  • Immunomodulation
  • Mimetics
  • Peptides

ASJC Scopus subject areas

  • Biochemistry

Cite this

Immunomodulatory peptides from IgSF proteins : A review. / Srinivasan, Mythily; Roeske, Roger W.

In: Current Protein and Peptide Science, Vol. 6, No. 2, 04.2005, p. 185-196.

Research output: Contribution to journalArticle

@article{85a1ce1c7cba4c5f9d84000fdc1921a9,
title = "Immunomodulatory peptides from IgSF proteins: A review",
abstract = "The immunoglobulin (Ig) domain is a highly conserved domain predominantly observed in cell surface proteins due to its ability to resist proteolysis. By mutation and selection the Ig domain has evolved to serve diverse biological functions including growth and development, signaling, adhesion and protein-carbohydrate interactions. Collectively, proteins with Ig-like domain constitute the immunoglobulin superfamily (IgSF). The IgSF proteins make up over 2{\%} of human genes constituting the largest gene family in the human genome. Analogous to the complementarity determining regions (CDR)s that form the antigen combining sites of the antibody, the high specificity of the IgSF receptor-ligand interaction is attributed to the sequence and structure of the CDR-like regions unique to each IgSF protein. Hence, CDR-like regions provide ideal templates for the design of mimetics that can potentially perturb specific IgSF receptor/ligand interactions. The determinants of binding are localized near the CDR-like regions, conformation is determined locally and is unique for each loop. In structure based drug design one of the approaches to identify lead agents is to map the receptor/ligand binding epitope onto a small peptide. Data from theoretical, structural and functional studies have been adopted in the design of novel peptide antagonists of the IgSF protein-protein interactions. Many peptide antagonists have shown significant therapeutic potential in multiple animal models. The design of the IgSF peptide analogs, rationale as therapeutic targets, functional efficacy and the clinical benefits are reviewed here.",
keywords = "IgSF, Immunomodulation, Mimetics, Peptides",
author = "Mythily Srinivasan and Roeske, {Roger W.}",
year = "2005",
month = "4",
doi = "10.2174/1389203053545426",
language = "English",
volume = "6",
pages = "185--196",
journal = "Current Protein and Peptide Science",
issn = "1389-2037",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Immunomodulatory peptides from IgSF proteins

T2 - A review

AU - Srinivasan, Mythily

AU - Roeske, Roger W.

PY - 2005/4

Y1 - 2005/4

N2 - The immunoglobulin (Ig) domain is a highly conserved domain predominantly observed in cell surface proteins due to its ability to resist proteolysis. By mutation and selection the Ig domain has evolved to serve diverse biological functions including growth and development, signaling, adhesion and protein-carbohydrate interactions. Collectively, proteins with Ig-like domain constitute the immunoglobulin superfamily (IgSF). The IgSF proteins make up over 2% of human genes constituting the largest gene family in the human genome. Analogous to the complementarity determining regions (CDR)s that form the antigen combining sites of the antibody, the high specificity of the IgSF receptor-ligand interaction is attributed to the sequence and structure of the CDR-like regions unique to each IgSF protein. Hence, CDR-like regions provide ideal templates for the design of mimetics that can potentially perturb specific IgSF receptor/ligand interactions. The determinants of binding are localized near the CDR-like regions, conformation is determined locally and is unique for each loop. In structure based drug design one of the approaches to identify lead agents is to map the receptor/ligand binding epitope onto a small peptide. Data from theoretical, structural and functional studies have been adopted in the design of novel peptide antagonists of the IgSF protein-protein interactions. Many peptide antagonists have shown significant therapeutic potential in multiple animal models. The design of the IgSF peptide analogs, rationale as therapeutic targets, functional efficacy and the clinical benefits are reviewed here.

AB - The immunoglobulin (Ig) domain is a highly conserved domain predominantly observed in cell surface proteins due to its ability to resist proteolysis. By mutation and selection the Ig domain has evolved to serve diverse biological functions including growth and development, signaling, adhesion and protein-carbohydrate interactions. Collectively, proteins with Ig-like domain constitute the immunoglobulin superfamily (IgSF). The IgSF proteins make up over 2% of human genes constituting the largest gene family in the human genome. Analogous to the complementarity determining regions (CDR)s that form the antigen combining sites of the antibody, the high specificity of the IgSF receptor-ligand interaction is attributed to the sequence and structure of the CDR-like regions unique to each IgSF protein. Hence, CDR-like regions provide ideal templates for the design of mimetics that can potentially perturb specific IgSF receptor/ligand interactions. The determinants of binding are localized near the CDR-like regions, conformation is determined locally and is unique for each loop. In structure based drug design one of the approaches to identify lead agents is to map the receptor/ligand binding epitope onto a small peptide. Data from theoretical, structural and functional studies have been adopted in the design of novel peptide antagonists of the IgSF protein-protein interactions. Many peptide antagonists have shown significant therapeutic potential in multiple animal models. The design of the IgSF peptide analogs, rationale as therapeutic targets, functional efficacy and the clinical benefits are reviewed here.

KW - IgSF

KW - Immunomodulation

KW - Mimetics

KW - Peptides

UR - http://www.scopus.com/inward/record.url?scp=18144368957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144368957&partnerID=8YFLogxK

U2 - 10.2174/1389203053545426

DO - 10.2174/1389203053545426

M3 - Article

C2 - 15853654

AN - SCOPUS:18144368957

VL - 6

SP - 185

EP - 196

JO - Current Protein and Peptide Science

JF - Current Protein and Peptide Science

SN - 1389-2037

IS - 2

ER -